Portfolio Lab

Charles River Laboratories International, Inc.

  • Stock
  • Ticker CRL
  • ISIN US1598641074
  • NYSE

Health care · Biotechnology · USA

$314.32 −4.15%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Charles River Laboratories International, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CRLGlobal equities (VT)

$10,000 grew to $43,390. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −78.2% in 04/2025, measured from the peak in 09/2021. The old peak has not been reached again yet.

1-year return
+93.9%
5-year return p.a.
−3.7%
10-year return p.a.
+15.8%
Volatility p.a.
35.5%
Largest decline
−78.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue1,0039841,0321,0059949961,004983
Operating income-16875100134-283120120203
EBITDA-66195220219-205187187275
Net income-214255254-277-15-1.5333
Earnings per share-4.170.501.061.10-5.56-0.30-0.036.86
Balance sheet
Total assets7,5287,5827,5617,5147,1357,7307,5327,452
Liabilities4,0204,3414,1614,0633,9244,7424,6444,176
Equity3,4623,1943,3533,4053,1652,9412,8403,227
Cash195229183207214192192200
Cash flow
Operating cash flow15917220521414841180254
Capital expenditure-76-59-35-36-89-56-31-47
Free cash flow8411216917859-15149207

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +63.6%, weakest 2022 at −42.2%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$6.86
5 Aug 2026−$0.03
7 May 2026−$0.30
18 Feb 2026−$5.56
5 Nov 2025$1.10
6 Aug 2025$1.06
7 May 2025$0.50
19 Feb 2025−$4.17
6 Nov 2024$1.33
7 Aug 2024$1.74
9 May 2024$1.30
14 Feb 2024$3.64

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€14bn
Market cap in trading currency
$15.1bn
Enterprise value
$14.9bn
P/E
324.0
P/S
3.79
P/B
4.67
EV/Sales
3.74
EV/EBITDA
33.5
Earnings yield
0.3%
FCF yield
2.7%

Results (last four quarters)

Revenue
$3.98bn
Gross profit
–
EBITDA
$444m
Net income
$40.2m
Earnings per share
$0.97
Revenue per share
$82.99
Revenue growth
−2.2%
Earnings growth
+512.0%

Profitability

Gross margin
–
Operating margin
4.0%
Net margin
1.0%
Return on equity
1.2%
Return on assets
0.5%

Balance sheet and cash flow

Cash
$200m
Cash per share
$4.18
Financial debt
$2.10m
Debt/equity %
0
Current ratio
1.41
Book value per share
$67.35
Operating cash flow
$622m
Free cash flow
$400m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
47.9m
Volume
1.15m
Avg. volume 3 months
1.06m
Relative volume
1.1

Price and technicals

Price
$314.32
1 day
−4.2%
52-week high
$376.10
52-week low
$149.93
Distance to 52-week high
−16.4%
Distance to 52-week low
+109.6%
Distance to 50-day line
−0.5%
Distance to 200-day line
+36.1%
RSI (14)
43
Volatility 1M
59.5%

Performance

1 week
−7.0%
1 month
−7.5%
3 months
+5.3%
6 months
+96.1%
YTD
+57.6%
1 year
+94.5%

Dates

Fiscal year end
27 Dec 2025
Most recent quarter
26 Sep 2026

Frequently asked questions

How has CRL performed since 11/2016?

$10,000 grew to $43,390 by 20 Nov 2026, which is +15.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CRL?

Volatility was 35.5% per year, measured on monthly returns. The largest decline from a peak was −78.2%, with the low in 04/2025.

How does CRL compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, CRL returned +15.8% at 35.5%. The correlation of monthly returns was 0.56; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Charles River Laboratories International, Inc. (CRL)